EyePoint Pharmaceuticals Inc EYPT:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/26/21 EST
10.81quote price arrow down-0.22 (-1.99%)
Volume
321,917
52 week range
3.51 - 15.06

...

Loading . . .

KEY STATS

  • Open11.03
  • Day High11.17
  • Day Low10.40
  • Prev Close10.81
  • 52 Week High15.06
  • 52 Week High Date02/18/21
  • 52 Week Low3.51
  • 52 Week Low Date10/28/20
  • Market Cap295.00M
  • Shares Out27.29M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta1.31
  • 1 Year % Change-16.2

RATIOS/PROFITABILITY

  • EPS (TTM)-3.43
  • P/E (TTM)-3.15
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-30.278M
  • ROE (MRQ)-342.81%
  • Revenue (MRQ)35.94M
  • Gross Margin (MRQ)86.96%
  • Net Margin (MRQ)-112.23%
  • Debt To Equity (MRQ)669.46%

EVENTS

  • Earnings Date03/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest EyePoint Pharmaceuticals Inc News

There is no recent news for this security.

Latest EYPT News From Our Partners

QUOTE FINDER

Profile

MORE
Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU)...
Goran Ando M.D.
Chairman
Nancy Lurker
President
George Elston
Chief Financial Officer
Said Saim Ph.D.
Chief Technology Officer
Address
480 Pleasant St Ste B300
Watertown, MA
02472-2468
United States